Adams Hopeful For Mucinex Patent Despite Initial USPTO Decision
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics expects its most recent patent on Mucinex brand OTC cough/cold remedies to protect the product line's market exclusivity until 2020, despite a challenge to an earlier patent on the products
You may also be interested in...
Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March
Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006
Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March
Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006
Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March
Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006